Did NEU make a mistake by indicating that they would not be prepared to consider any offers until after the FDA meeting?
Has that been the catalyst for the $10 decline in the SP?
Did giving potential acquirers that information allow them to subsequently control the situation and potentially drop an acceptable t/o price by $1 billion+?
I just have the feeling that NEU is not as firmly planted in the drivers seat as should be the case given the NNZ2591 results.
The Whens and Whys of Top Biotech M&A Deals, page-22
-
- There are more pages in this discussion • 21 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.26 |
Change
-0.220(1.42%) |
Mkt cap ! $1.947B | |||
| Open | High | Low | Value | Volume |
| $15.20 | $15.33 | $15.02 | $4.390M | 289.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 263 | $15.26 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.27 | 571 | 11 |
View Market Depth
| Last trade - 14.06pm 22/08/2024 (20 minute delay) ? |
| NEU (ASX) Chart |